|
⚲
|
| Keyboard |
| LSP 7 Cooperative UA
✚
|
|
|---|---|
| CIK # | 0001876264 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001876264] | |
| 4 | [0001876264] | |
| D | [0001876264] | |
| SC 13D | [0001876264] | |
| SC 13G | [0001876264] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| LSP 7 Cooperative UA | Agomab Therapeutics NV | [2026-02-17] |
| LSP 7 Cooperative UA | Evommune Inc | [2025-11-14] |
| LSP 7 Cooperative UA | Oculis Holding AG | [2024-02-09] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| LSP 7 Cooperative UA | |
| Evommune Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Evommune Inc EVMN
Common Stock
|
2026-02-17 | Grant | 358,680 | $27.88 | 9,999,998 |
|
Evommune Inc EVMN
Common Stock
|
2025-11-07 | Conversion | 3,367,133 | ||
|
Evommune Inc EVMN
Common Stock
|
2025-11-07 | Buy | 1,562,500 | $16.00 | 25,000,000 |
|
Evommune Inc EVMN
Series B Preferred Stock · derivative
|
2025-11-07 | Conversion | 5,090,000 | ||
|
Evommune Inc EVMN
Series A Preferred Stock · derivative
|
2025-11-07 | Conversion | 15,493,466 | ||
|
Evommune Inc EVMN
Series C Preferred Stock · derivative
|
2025-11-07 | Conversion | 6,585,011 |